Sequella, a Maryland, USA-based clinical-stage biopharmaceutical company focused on commercializing products to treat diseases of epidemic potential, says that the Food and Drug Administration and the European Medicines Agency (EMEA) independently reviewed its lead drug compound, SQ109 (N-adamantany1-N'-geranyl-ethylendiamine), with both agencies granting it orphan drug status for the treatment of tuberculosis. SQ109 shows excellent in vitro and in vivo activity against drug-susceptible and drug-resistant TB bacteria, including XDR-TB. Furthermore, the agent synergizes with other TB drugs in experimental animal models of the disease, and could result in new drug combinations that have much greater activity than the current standard-of-care products, the company says.
Carol Nacy, founder and chief executive of Sequella, said: "with the resurgence of TB in a new drug-resistant form, it is clear there is a need to readdress the treatment of this infectious and deadly disease. To accelerate our clinical programs, we will continue to work closely with the FDA's Office of Orphan Products Development and the EMEA's Committee for Orphan Medicinal Products as we move through the clinical and regulatory process."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze